Daiichi Sankyo Company, Limited (DSKYF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 09:44AM EDT. Market open.
| Previous close | 35.62 |
| Open | 37.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 36.67 - 37.20 |
| 52-week range | 23.45 - 37.91 |
| Volume | |
| Avg. volume | 23,498 |
| Market cap | 70.622B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 54.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.39 (1.09%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
© 2024 Yahoo. All rights reserved.